Ocugen Inc. (OCGN)
NASDAQ: OCGNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
OCGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $260.55M
- EPS (TTM)
- -$0.20
- Dividend yield
- None
- 52-week range
- 0.691 – 2.73
- Day range
- 0.71 – 0.8198
- Volume / Avg
- 6.19M / 7.34M
- Beta
- —
- Shares outstanding
- 339.31M
52-week range
OCGN stock today
Shares of Ocugen (OCGN) finished higher on Nov 20 at $0.7679, a gain of 4.79% or $0.0351 per share, versus the S&P 500's 3.70% decline. Shares are 71.8% below their 52-week high of $2.73, set on Mar 17, 2026 and 11.1% above the 52-week low of $0.691, near the bottom of the past year's range. OCGN is down 43.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 33.8%.
Ocugen has posted a net loss over the last twelve months (EPS of -$0.20), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Ocugen
Company profileOcugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Shankar Musunuri M.B.A., Ph.D.
- Headquarters
- Malvern, PA
- Employees
- 116
- IPO year
- 2014
- Website
- ocugen.com
Financial highlights
Full financialsIn fiscal 2025, Ocugen generated $4.4 million in revenue, up 8.8% from fiscal 2024. Ocugen reported a net loss of $67.8 million, compared with a loss of $54.1 million a year earlier. Operating margin was -1425.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $4.41M | $4.05M | $6.04M | $2.49M | $0 |
| Growth | +8.83% | -32.82% | +142.60% | — | -100.00% |
| Net income | $-67.85M | $-54.05M | $-63.08M | $-86.80M | $-58.37M |
| EPS (diluted) | — | — | $-0.26 | $-0.40 | $-0.30 |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$12.17+1484.84%
- Strong buy 1
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.01 vs $-0.06
- Surprise
- +83.33%
OCGN news
All OCGN news- Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEANGlobeNewswire
- Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock RisesNasdaqOCGN, TGTX, TARS
- Ocugen (OCGN) Q3 2026 Earnings Call TranscriptNasdaq
- Ocugen Provides Business Update with Third Quarter 2026 Financial ResultsGlobeNewswire
- Ocugen to Participate in Upcoming November Investor and Industry ConferencesGlobeNewswire
- Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4GlobeNewswire
- Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North AfricaGlobeNewswire
Ocugen peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EIKNEikon Therapeutics Inc. | 4.74 | -0.42% | $256.84M | vs OCGN |
| SABSSAB Biotherapeutics Inc. | 2.81 | -3.44% | $253.15M | vs OCGN |
| EDITEditas Medicine Inc. | 1.64 | -4.09% | $253.12M | vs OCGN |
| AGMBAgomAb Therapeutics NV ADR | 5.45 | -3.02% | $268.40M | vs OCGN |
| KYTXKyverna Therapeutics Inc. | 4.26 | -2.52% | $269.33M | vs OCGN |
| AGENAgenus Inc. | 5.97 | -2.77% | $270.12M | vs OCGN |
| LXEOLexeo Therapeutics Inc. | 2.96 | +0.34% | $245.05M | vs OCGN |
| PLXProtalix BioTherapeutics Inc. (DE) | 2.90 | -5.23% | $244.52M | vs OCGN |
Indexes, lists and sector
Ocugen stock FAQ
What is Ocugen's stock price today?
OCGN last traded at $0.7679 as of Nov 20, 4:00 PM EST, up 4.79% on the day. Prices are delayed at least 15 minutes.
Does Ocugen pay a dividend?
No. Ocugen does not currently pay a regular cash dividend.
Who is Ocugen's CEO?
Dr. Shankar Musunuri M.B.A., Ph.D. is the chief executive officer of Ocugen Inc., which has about 116 employees.
Has OCGN ever split its stock?
Yes. The most recent OCGN stock split was a 1-for-60 split on Sep 30, 2019.
What is the OCGN 52-week high?
The 52-week high for OCGN is $2.73 and the 52-week low is $0.691. The stock is currently 71.8% below its high.